The global self-expanding covered stents market size was estimated at USD 743.8 million in 2025 and is projected to reach USD 1,091.7 million by 2033, growing at a CAGR of 5.0% from 2026 to 2033. The increasing prevalence of peripheral artery disease and aortoiliac occlusive disease, rising incidence of Aneurysm, are driving the demand for effective vascular interventions, thereby boosting the adoption of self-expanding covered stents.

The section below outlines the key factors driving the growth of the self-expanding covered stents (SX-CS) market, highlighting the rising prevalence of peripheral artery disease and aortoiliac occlusive disease, along with the increasing demand for minimally invasive vascular interventions. It also examines the role of technological advancements, such as Nitinol-based stent designs and improved Polytetrafluoroethylene coverings, as well as the expanding use of SX-CS in complex procedures, including Endovascular Aneurysm Repair, Fenestrated Endovascular Aneurysm Repair, and Branched Endovascular Aneurysm Repair, thereby strengthening their adoption across healthcare settings.

Download a free sample copy of the Self-expanding Covered Stents Market report to understand detailed coverage and inclusions in the final report

The increasing incidence of Peripheral Artery Disease and Aortoiliac Occlusive Disease is driving demand for durable and flexible stent solutions. SX-CS is widely preferred due to its ability to provide long-term patency and vessel support in complex lesions. In May 2024, the Centers for Disease Control and Prevention highlighted that PAD affects millions of adults in the U.S., significantly increasing the need for endovascular interventions.

Continuous innovation in stent design improves treatment outcomes

Ongoing advancements in stent technologies are enhancing flexibility, deliverability, and suitability for complex vascular anatomies. These innovations are improving procedural efficiency and expanding the use of advanced stents, thereby supporting overall market growth. BD Fluency Plus Endovascular Stent Graft is a self-expanding covered nitinol stent encapsulated with ePTFE, designed for iliac and femoral artery interventions, offering flexibility, accurate deployment, and durable patency in complex lesions. The system features a nitinol-based self-expanding design that provides sustained radial force, flexibility, and the ability to adapt to dynamic vascular anatomies, while the ePTFE covering acts as a barrier to prevent plaque prolapse and support effective sealing. Similarly, in March 2024, W. L. Gore & Associates continued advancements in its VIABAHN endoprosthesis platform, enhancing performance in complex peripheral artery interventions.

Post-Market Evidence Supporting SX-CS Safety, Patency, and Durability in Iliac Lesions

Post-market clinical results validating the safety and durability of SX-CS in challenging iliac anatomy boost market growth. According to an Endovascular Today article published in December 2025, a recent real-world clinical instance illustrating the performance of self-expanding covered stents is the Solaris SX iliac post-market clinical follow-up study, which reported excellent outcomes through 12 months. In this prospective multicenter study across nine European sites, the Solaris SX device achieved primary patency of over 95 % at 6 months and approximately 94 % at 12 months, along with a significant improvement in ankle brachial index from 0.547 at baseline to 0.927 at 12 months, and no device-related serious adverse events through 30 days, representing both safety and durability in treating challenging iliac artery lesions. These findings suggest strong potential for SX CS platforms in a range of peripheral applications, including external iliac and related segment interventions.

Technological advancements in stent design and materials

Innovations in Nitinol self-expanding frameworks and Polytetrafluoroethylene coverings are improving flexibility, durability, and clinical outcomes. These advancements support usage in complex anatomies and high-risk patients. In January 2026, W. L. Gore & Associates, Inc. received FDA approval for the VIABAHN FORTEGRA Venous Stent, a self-expanding device indicated for deep venous disease in the inferior vena cava and iliofemoral veins. The approval was supported by an 89-patient international study showing 83.4% 12-month primary patency with no major device-related safety events.

Need deeper insights? Customize this report for your market

Increasing Clinical R&D Activities Driving Innovation and Product Development in SX-CS

An increased focus on clinical research and development is driving innovation and the adoption of advanced vascular devices, including self-expanding covered stents. Ongoing clinical trials are evaluating safety, effectiveness, and long-term outcomes, thereby accelerating product approvals and expanding treatment options for complex vascular diseases. In March 2024, Becton, Dickinson and Company initiated the AGILITY clinical study to evaluate its investigational self-expanding covered stent for the treatment of Peripheral Artery Disease, enrolling patients across multiple global sites to assess long-term safety and effectiveness.

Key Self-expanding Covered Stents Company Insights

Key players operating in the self-expanding covered stents market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling market growth.

Key Self-expanding Covered Stents Companies:

The following key companies have been profiled for this study on the self-expanding covered stents market.

• L. Gore & Associates, Inc.
• Solaris Endovascular
• BD (Angiomed GmbH & Co. Medizintechnik KG)
• LeMaitre Vascular, Inc.
• Endologix LLC
• Artivion, Inc
• Merit Medical Systems

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…

Discover Our New Consumer Insights Service : https://www.grandviewresearch.com/services/consumer-insights